pulmonx

Pulmonx Corporation is a commercial-stage medical technology company focused on developing and commercializing minimally invasive treatments for severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's flagship product, the Zephyr® Endobronchial Valve, is an FDA-approved implant designed to reduce lung hyperinflation... by collapsing diseased portions of the lung, thereby improving breathing and quality of life for patients. Pulmonx also offers diagnostic and planning tools such as the Chartis® Pulmonary Assessment System and the StratX®/LungTraX® platforms, which help identify appropriate candidates for treatment through advanced lung imaging and functional assessment. With over 40,000 patients treated globally, Pulmonx is a leader in the interventional pulmonology space.Read More